Daratumumab Injection ( DrugBank: Daratumumab )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
16クロウ・深瀬症候群1
49全身性エリテマトーデス1

16. クロウ・深瀬症候群


臨床試験数 : 13 薬物数 : 18 - (DrugBank : 8) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 81
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04396496
(ClinicalTrials.gov)
September 22, 202015/5/2020Treatment of POEMS Syndrome With DaratumumabA Phase II Trial for the Treatment of POEMS Syndrome With DaratumumabPOEMS SyndromeDrug: Daratumumab InjectionUniversity of ArkansasJanssen Scientific Affairs, LLCRecruiting18 YearsN/AAll10Phase 2United States

49. 全身性エリテマトーデス


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04810754
(ClinicalTrials.gov)
June 30, 202111/3/2021An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus ErythematosusA Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: Daratumumab InjectionCharite University, Berlin, GermanyJanssen-Cilag G.m.b.H;Labor Berlin-Charité Vivantes G.m.b.H;Deutsches Rheuma-Forschungszentrum Berlin (DRFZ);Charité Clinical Trial Office (CTO)Not yet recruiting18 Years60 YearsAll10Phase 2NULL